{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:28:18Z","timestamp":1761766098817,"version":"3.44.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ucl.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T19:40:22Z","timestamp":1473450022000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging Systemic Therapies for the Management of Penile Cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Shilpa","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2016.06.009_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ucl.2016.06.009_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(04)01427-5","article-title":"Penile carcinoma: a challenge for the developing world","volume":"5","author":"Misra","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.urology.2010.03.003","article-title":"Epidemiology and natural history of penile cancer","volume":"76","author":"Pow-Sang","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.06.009_bib4","first-page":"7201","article-title":"Contemporary management of penile cancer: greater than 15\u00a0year MSKCC experience","volume":"21","author":"Moses","year":"2014","journal-title":"Can J Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1464-410X.2001.00380.x","article-title":"Lymphadenectomy for squamous cell carcinoma of the penis. Part 1: diagnosis of lymph node metastasis","volume":"88","author":"Horenblas","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.6004\/jnccn.2013.0195","article-title":"New treatment guidelines for penile cancer","volume":"11","author":"Spiess","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.ucl.2016.06.009_bib7","first-page":"1637","article-title":"Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy","volume":"156","author":"Lopes","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00120-009-2108-z","article-title":"The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics","volume":"48","author":"Protzel","year":"2009","journal-title":"Urologe A"},{"key":"10.1016\/j.ucl.2016.06.009_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/annonc\/mds635","article-title":"Penile cancer: current therapy and future directions","volume":"24","author":"Sonpavde","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib10","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib11","first-page":"66","article-title":"Cis-diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study","volume":"141","author":"Gagliano","year":"1989","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib12","first-page":"289","article-title":"An appraisal of the efficacy of bleomycin in epidermoid carcinoma of the penis","volume":"4","author":"Ahmed","year":"1984","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ucl.2016.06.009_bib13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/1097-0142(197911)44:5<1563::AID-CNCR2820440503>3.0.CO;2-S","article-title":"Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma","volume":"44","author":"Sklaroff","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2016.06.009_bib14","first-page":"465","article-title":"Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer","volume":"132","author":"Ahmed","year":"1984","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib15","first-page":"265","article-title":"Metastatic carcinoma of the penis: complete remission after high dose methotrexate chemotherapy","volume":"122","author":"Garnick","year":"1979","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib16","first-page":"630","article-title":"Cisplatin and 5-fluorouracil in advanced cancer of the penis","volume":"147","author":"Shammas","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib17","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1111\/j.1464-410X.2012.11453.x","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0090-4295(93)90273-D","article-title":"Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy","volume":"42","author":"Kattan","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.06.009_bib19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdn149","article-title":"A\u00a0phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)","volume":"19","author":"Theodore","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.urology.2003.12.026","article-title":"Major tumor\u00a0regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer","volume":"63","author":"Joerger","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.06.009_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bju.13054","article-title":"Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile\u00a0squamous cell carcinoma","volume":"117","author":"Houede","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.urolonc.2007.10.015","article-title":"Cisplatin and gemcitabine in the management of metastatic penile cancer","volume":"27","author":"Power","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib23","first-page":"1284","article-title":"Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract","volume":"146","author":"Dexeus","year":"1991","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib24","first-page":"1823","article-title":"Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study","volume":"161","author":"Haas","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1464-410X.2006.06496.x","article-title":"Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma","volume":"98","author":"Hakenberg","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib26","first-page":"1770","article-title":"Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin","volume":"160","author":"Corral","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2007.02.006","article-title":"Neoadjuvant chemotherapy in advanced penile carcinoma","volume":"52","author":"Leijte","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib28","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2016.06.009_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.urolonc.2013.10.007","article-title":"Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy","volume":"32","author":"Pond","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e32834d237b","article-title":"Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity","volume":"23","author":"Aparicio","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ucl.2016.06.009_bib31","first-page":"1335","article-title":"Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma","volume":"177","author":"Bermejo","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/02841868809094366","article-title":"Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis","volume":"27","author":"Pizzocaro","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib33","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bju.12946","article-title":"Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy","volume":"117","author":"Dickstein","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000480874","article-title":"Up-to-date management of carcinoma of the penis","volume":"32","author":"Pizzocaro","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0974-7796.102659","article-title":"Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer","volume":"4","author":"Noronha","year":"2012","journal-title":"Urol Ann"},{"issue":"Suppl 6","key":"10.1016\/j.ucl.2016.06.009_bib37","article-title":"Treatment of metastatic penile cancer in the adjuvant setting with ifosfamide, paclitaxel, and cisplatin: a single institution experience","volume":"31","author":"O'Reilly","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.06.009_bib39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2013.0075","article-title":"Penile cancer: clinical practice guidelines in oncology","volume":"11","author":"Clark","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"Suppl 6","key":"10.1016\/j.ucl.2016.06.009_bib40","doi-asserted-by":"crossref","first-page":"vi115","DOI":"10.1093\/annonc\/mdt286","article-title":"Penile cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Van Poppel","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib41","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2007.12.3182","article-title":"Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma","volume":"25","author":"Heideman","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/85.1.19","article-title":"History of circumcision, medical conditions, and sexual activity and risk of penile cancer","volume":"85","author":"Maden","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2016.06.009_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bmj.295.6609.1306","article-title":"Penile cancer: is there an epidemiological role for smoking and sexual behaviour?","volume":"295","author":"Hellberg","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.ucl.2016.06.009_bib44","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/jnci\/87.22.1705","article-title":"Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma","volume":"87","author":"Gregoire","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2016.06.009_bib45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(07)70137-7","article-title":"Molecular and genetic pathways in penile cancer","volume":"8","author":"Kayes","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib46","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1158\/1078-0432.CCR-09-0882","article-title":"DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma","volume":"15","author":"Kayes","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2016.06.009_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (catalogue of somatic mutations in cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2016.06.009_bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2559.2011.03762.x","article-title":"The retinoblastoma protein\/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma","volume":"58","author":"Stankiewicz","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.ucl.2016.06.009_bib49","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2016.06.009_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","article-title":"Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"issue":"Suppl 2S","key":"10.1016\/j.ucl.2016.06.009_bib51","article-title":"Whole-exome sequencing (WES) of penile squamous cell carcinoma (PSCC) to identify multiple recurrent mutations","volume":"34","author":"Naik","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ucl.2016.06.009_bib52","article-title":"Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets","volume":"33","author":"Mehta","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ucl.2016.06.009_bib53","article-title":"Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy","volume":"33","author":"Mehta","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib54","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1023\/A:1011177318162","article-title":"The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy","volume":"12","author":"Pedersen","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3747\/co.v17i1.471","article-title":"EGFR overexpression in squamous cell carcinoma of the penis","volume":"17","author":"Lavens","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib56","first-page":"1483","article-title":"Characterization of the EGF receptor status in penile cancer: retrospective analysis of the course of the disease in 45 patients","volume":"48","author":"Borgermann","year":"2009","journal-title":"Urologe A"},{"key":"10.1016\/j.ucl.2016.06.009_bib57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2015.993377","article-title":"The epidermal growth factor receptors as biological targets in penile cancer","volume":"15","author":"Di Lorenzo","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ucl.2016.06.009_bib58","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.humpath.2013.07.012","article-title":"The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases","volume":"44","author":"Chaux","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ucl.2016.06.009_bib59","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/17460441.2014.925875","article-title":"Novel targeted therapies for the treatment of penile cancer","volume":"9","author":"Agarwal","year":"2014","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.ucl.2016.06.009_bib60","doi-asserted-by":"crossref","first-page":"e62175","DOI":"10.1371\/journal.pone.0062175","article-title":"Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma","volume":"8","author":"Gou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2016.06.009_bib61","doi-asserted-by":"crossref","first-page":"e17517","DOI":"10.1371\/journal.pone.0017517","article-title":"Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas","volume":"6","author":"Stankiewicz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2016.06.009_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.06.009_bib63","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1200\/JCO.2011.34.8367","article-title":"Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis","volume":"29","author":"Necchi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.urology.2013.08.074","article-title":"Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3\u00a0cases","volume":"83","author":"Brown","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.06.009_bib65","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12032-013-0702-9","article-title":"Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67","volume":"30","author":"Li","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000315432","article-title":"Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report","volume":"85","author":"Zhu","year":"2010","journal-title":"Urol Int"},{"issue":"Suppl","key":"10.1016\/j.ucl.2016.06.009_bib67","article-title":"Phase II study of pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin-based chemotherapy: PAZOPEN study","volume":"33","author":"Climent","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"53","key":"10.1016\/j.ucl.2016.06.009_bib68","first-page":"e51","article-title":"Implications for human papillomavirus in penile cancer","volume":"32","author":"Flaherty","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib69","first-page":"178","article-title":"Penile cancer and human papillomavirus infection","volume":"19","author":"Zhai","year":"2013","journal-title":"Zhonghua Nan Ke Xue"},{"key":"10.1016\/j.ucl.2016.06.009_bib70","first-page":"2719","article-title":"Association between HPV DNA and disease specific survival in patients with penile cancer","volume":"93","author":"Zhai","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.ucl.2016.06.009_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/PAS.0b013e3181c76a49","article-title":"The basaloid cell is the best tissue marker for human papillomavirus in invasive penile squamous cell carcinoma: a study of 202 cases from Paraguay","volume":"34","author":"Cubilla","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ucl.2016.06.009_bib72","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/1097-0142(20010615)91:12<2315::AID-CNCR1263>3.0.CO;2-C","article-title":"Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy","volume":"91","author":"Bezerra","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2016.06.009_bib73","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/ijc.21961","article-title":"Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival","volume":"119","author":"Lont","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ucl.2016.06.009_bib74","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib75","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.06.009_bib76","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ucl.2016.06.009_bib77","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2016.06.009_bib78","article-title":"A\u00a0phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV\u2013associated head and neck (H\/N) cancer","volume":"32","author":"Seiwert","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl\u00a05","key":"10.1016\/j.ucl.2016.06.009_bib79","article-title":"Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ucl.2016.06.009_bib80","article-title":"Programmed death ligand-1 (PD-L1) expression in penile squamous cell carcinoma","volume":"33","author":"Wang","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2016.06.009_bib81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2008.07.014","article-title":"Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results","volume":"55","author":"Pizzocaro","year":"2009","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014316300283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014316300283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:31:27Z","timestamp":1758807087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014316300283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0094014316300283"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2016.06.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Systemic Therapies for the Management of Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}